Clinical Study

Otsuka Tolvaptan Open Label Rollover Study For Adpkd

Posted Date: Dec 26, 2017

Investigator:Shashi Kant

Co-Investigator:Karen Case

Specialties:Kidney Disease, Nephrology

Type of Study:Drug

Tolvaptan is being studied as a possible treatment for autosomal dominant polycystic kidney disease (ADPKD). ADPKD is a disease that causes kidney cysts (cysts are like fluid-filled balloons), worsening kidney function, blood in the urine, kidney pain, high blood pressure, kidney stones, kidney infections, and cysts in the liver or other parts of the body and sometimes heart or blood vessel abnormalities. The kidneys of patients with ADPKD respond abnormally to a hormone in the bloodstream called vasopressin. This abnormal response can cause the cysts in the kidneys, associated with the disease, to grow more quickly. Tolvaptan blocks the effect of this hormone in the kidneys meaning that it can slow the growth of the kidney cysts when taken for a long time.

Colon Cancer Research Study

Looking at a Treatment to Reduce Colon Cancer Recurrence

What: The purpose of this study is to evaluate the effects of an oral drug
called celecoxib when combined with FOLFOX chemotherapy in
patients with colon cancer who have previously been treated with
surgery. FOLFOX chemotherapy is a standard treatment used to
prevent colon cancer from coming back and consists of three drugs:
5-fluorouracil, leucovorin and oxaliplatin. This study will also look
at whether receiving FOLFOX for 6 treatments is as good as 12
treatments in preventing colon cancer from returning. Currently, the standard of care for colon cancer is 12 treatments with FOLFOX. This trial will explore whether 6 treatments are as effective as 12 treatments and whether side effects can be reduced with fewer treatments.

Who: Adults 18 years or older who have cancer of the colon, which has been surgically removed, but has spread to the lymph nodes may be eligible to participate.

Details:For more information, contact the UC Cancer Institute at kastla@ucmail.uc.edu or 513-584-7698.